{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,30]],"date-time":"2025-11-30T13:47:18Z","timestamp":1764510438574},"reference-count":26,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"5","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2012,9]]},"DOI":"10.1097\/ppo.0b013e31826aed6d","type":"journal-article","created":{"date-parts":[[2012,9,21]],"date-time":"2012-09-21T21:40:28Z","timestamp":1348263628000},"page":"383-389","source":"Crossref","is-referenced-by-count":5,"title":["What Is the Best Initial Therapy for a Patient With Symptomatic Low-Grade Follicular Lymphoma?"],"prefix":"10.1097","volume":"18","author":[{"given":"Vaishalee P.","family":"Kenkre","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Brad S.","family":"Kahl","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"key":"R1-2-20210203","first-page":"213","article-title":". Follicular lymphoma: expanding therapeutic options.","volume":"19","author":"Ganti","year":"2005","journal-title":"Oncology"},{"key":"R3-2-20210203","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1056\/NEJMcibr067155","article-title":"A closer look at follicular lymphoma.","volume":"356","author":"Staudt","year":"2007","journal-title":"N Engl J Med"},{"issue":"suppl 5","key":"R4-2-20210203","first-page":"75","article-title":"Natural history of and therapy for indolent non-Hodgkins Lymphoma.","volume":"20","author":"Horning","year":"1993","journal-title":"Semin Oncol"},{"key":"R5-2-20210203","doi-asserted-by":"crossref","first-page":"7565","DOI":"10.1200\/JCO.2004.00.9217","article-title":". Tositumomab and iodine-131 tositumomab produces durable complete remissions in a subset of heavily pretreated patients with low-grade and transformed non-Hodgkins lymphomas.","volume":"25","author":"Fisher","year":"2005","journal-title":"J Clin Oncol"},{"key":"R6-2-20210203","doi-asserted-by":"crossref","first-page":"4019","DOI":"10.1200\/JCO.2005.04.503","article-title":". Improved survival of follicular lymphoma patients in the United States.","volume":"23","author":"Swenson","year":"2005","journal-title":"J Clin Oncol"},{"key":"R7-2-20210203","doi-asserted-by":"crossref","first-page":"1582","DOI":"10.1200\/JCO.2005.03.3696","article-title":". Improvement of overall and failure-free survival in stage IV follicular lymphoma: 25 years of treatment experience at the University of Texas M.D. Anderson Cancer Center.","volume":"24","author":"Liu","year":"2006","journal-title":"J Clin Oncol"},{"key":"R8-2-20210203","doi-asserted-by":"crossref","first-page":"1110","DOI":"10.1200\/JCO.1997.15.3.1110","article-title":". Comparison in low-tumor-burden follicular lymphomas between an initial no-treatment policy, prednimustine, or interferon alfa: a randomized study from the Groupe dEtude des Lymphomes Folliculaires.","volume":"15","author":"Brice","year":"1997","journal-title":"J Clin Oncol"},{"key":"R9-2-20210203","doi-asserted-by":"crossref","first-page":"1258","DOI":"10.1182\/blood-2003-12-4434","article-title":". Follicular lymphoma international prognostic index.","volume":"104","author":"Solal-Celigny","year":"2004","journal-title":"Blood"},{"key":"R10-2-20210203","doi-asserted-by":"crossref","first-page":"4555","DOI":"10.1200\/JCO.2008.21.3991","article-title":". Follicular lymphoma international prognostic index 2: a new prognostic index for follicular lymphoma developed by the international follicular lymphoma prognostic factor project.","volume":"27","author":"Federico","year":"2009","journal-title":"J Clin Oncol"},{"key":"R13-2-20210203","doi-asserted-by":"crossref","first-page":"3725","DOI":"10.1182\/blood-2005-01-0016","article-title":". Frontline therapy with rituximab added to the combination of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) significantly improves the outcome for patients with advanced-stage follicular lymphoma compared with therapy with CHOP alone: results of a prospective randomized study of the German Low-Grade Lymphoma Study Group.","volume":"106","author":"Hiddeman","year":"2005","journal-title":"Blood"},{"key":"R14-2-20210203","doi-asserted-by":"crossref","first-page":"4579","DOI":"10.1200\/JCO.2007.13.5376","article-title":". Phase III study of R-CVP compared with cyclophosphamide, vincristine, and prednisone alone in patients with previously untreated advanced follicular lymphoma.","volume":"26","author":"Marcus","year":"2008","journal-title":"J Clin Oncol"},{"key":"R17-2-20210203","doi-asserted-by":"crossref","first-page":"1417","DOI":"10.1182\/blood-2004-08-3175","article-title":". CVP chemotherapy plus rituximab compared with CVP as first-line treatment for advanced follicular lymphoma.","volume":"105","author":"Marcus","year":"2005","journal-title":"Blood"},{"key":"R18-2-20210203","doi-asserted-by":"crossref","first-page":"1986","DOI":"10.1200\/JCO.2006.06.4618","article-title":". Rituximab added to first-line mitoxantrone, chlorambucil, and prednisolone chemotherapy followed by interferon maintenance prolongs survival in patients with advanced follicular lymphoma: an East German Study Group Hematology and Oncology Study.","volume":"25","author":"Herold","year":"2007","journal-title":"J Clin Oncol"},{"key":"R19-2-20210203","doi-asserted-by":"crossref","first-page":"4824","DOI":"10.1182\/blood-2008-04-153189","article-title":". Rituximab combined with chemotherapy and interferon in follicular lymphoma patients: results of the GELA-GOELAMS FL 2000 study.","volume":"112","author":"Salles","year":"2008","journal-title":"Blood"},{"key":"R21-2-20210203","doi-asserted-by":"crossref","first-page":"1590","DOI":"10.1200\/JCO.2005.03.7952","article-title":". Phase III intergroup study of fludarabine phosphate compared with cyclophosphamide, vincristine, and prednisone chemotherapy in newly diagnosed patients with stage III and IV low-grade malignant Non-Hodgkins lymphoma.","volume":"24","author":"Hagenbeek","year":"2006","journal-title":"J Clin Oncol"},{"key":"R22-2-20210203","doi-asserted-by":"crossref","first-page":"2654","DOI":"10.1200\/JCO.2004.07.170","article-title":". Fludarabine plus mitoxantrone with and without rituximab versus CHOP with and without rituximab as front-line treatment for patients with follicular lymphoma.","volume":"22","author":"Zinzani","year":"2004","journal-title":"J Clin Oncol"},{"key":"R28-2-20210203","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/S0140-6736(10)62175-7","article-title":". Rituximab maintenance for 2 years in patients with high tumour burden follicular lymphoma responding to rituximab plus chemotherapy (PRIMA): a phase 3, randomized controlled trial.","volume":"377","author":"Salles","year":"2010","journal-title":"Lancet"},{"key":"R29-2-20210203","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1056\/NEJMoa041511","article-title":". 131I-tositumomab therapy as initial treatment for follicular lymphoma.","volume":"352","author":"Kaminski","year":"2005","journal-title":"N Eng J Med"},{"key":"R30-2-20210203","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1056\/NEJMe048291","article-title":"Radioimmunotherapyhot new treatment for lymphoma.","volume":"352","author":"Connors","year":"2005","journal-title":"N Eng J Med"},{"key":"R31-2-20210203","doi-asserted-by":"crossref","first-page":"5156","DOI":"10.1200\/JCO.2008.17.2015","article-title":". Phase III trial of consolidation therapy with yttrium-90-ibritumomab tiuxetan compared with no additional therapy after first remission in advanced follicular lymphoma.","volume":"26","author":"Morschhauser","year":"2008","journal-title":"J Clin Oncol"},{"key":"R33-2-20210203","doi-asserted-by":"crossref","first-page":"2825","DOI":"10.1200\/JCO.1998.16.8.2825","article-title":". Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program.","volume":"16","author":"McLaughlin","year":"1998","journal-title":"J Clin Oncol"},{"key":"R34-2-20210203","doi-asserted-by":"crossref","first-page":"4480","DOI":"10.1200\/JCO.2010.28.4786","article-title":". Long-term follow-up of patients with follicular lymphoma receiving single-agent rituximab at two different schedules in trial SAKK 3598.","volume":"28","author":"Martinelli","year":"2010","journal-title":"J Clin Oncol"},{"key":"R35-2-20210203","doi-asserted-by":"crossref","first-page":"4416","DOI":"10.1182\/blood-2003-10-3411","article-title":". Prolonged treatment with rituximab in patients with follicular lymphoma significantly increases event-free survival and response duration compared with the standard weekly 4 schedule.","volume":"103","author":"Ghielmini","year":"2004","journal-title":"Blood"},{"key":"R36-2-20210203","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1182\/blood-2008-05-160200","article-title":". High-dose therapy followed by autologous purged stem cell transplantation and doxorubicin-based chemotherapy in patients with advanced follicular lymphoma: a randomized multicenter study by the GOELAMS with final results after a median follow-up of 9 years.","volume":"113","author":"Gyan","year":"2009","journal-title":"Blood"},{"key":"R37-2-20210203","doi-asserted-by":"crossref","first-page":"2667","DOI":"10.1182\/blood-2004-03-0982","article-title":". Myeloablative radiochemotherapy followed by autologous stem cell transplantation in first remission prolongs progression-free survival in follicular lymphomaresults of a prospective randomized trial of the German Low-Grade Lymphoma Study Group (GLSG).","volume":"104","author":"Lenz","year":"2004","journal-title":"Blood"},{"key":"R38-2-20210203","doi-asserted-by":"crossref","first-page":"4004","DOI":"10.1182\/blood-2007-10-116749","article-title":". Prospective, multicenter randomized GITMOIIL trial comparing intensive (R-HDS) versus conventional (CHOP-R) chemoimmunotherapy in high-risk follicular lymphoma at diagnosis: the superior disease control of R-HDS does not translate into an overall survival advantage.","volume":"111","author":"Ladetto","year":"2008","journal-title":"Blood"}],"container-title":["The Cancer Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/PPO.0b013e31826aed6d","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,5,14]],"date-time":"2021-05-14T05:26:42Z","timestamp":1620970002000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00130404-201209000-00002"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,9]]},"references-count":26,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2012]]}},"URL":"https:\/\/doi.org\/10.1097\/ppo.0b013e31826aed6d","relation":{},"ISSN":["1528-9117"],"issn-type":[{"value":"1528-9117","type":"print"}],"subject":[],"published":{"date-parts":[[2012,9]]}}}